Trial Profile
Protocol With Amendments 1 and 2: Phase I Randomised, Two-period 21 Day Crossover Study in Healthy Male and Female Volunteers to Compare the Steadystate Pharmacokinetics of Tiotropium Delivered From a Test pMDI Product With Spiriva Respimat
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Tiotropium bromide (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease; Cystic fibrosis
- Focus Pharmacokinetics
- 02 Jul 2018 Status changed from recruiting to completed.
- 16 Aug 2017 New trial record